Corementum

Cormentum is a pre-clinical stage biotechnology company dedicated to developing transformative therapies for cardiovascular diseases, with a primary focus on heart failure with preserved ejection fraction (HFpEF). Founded in 2023 based on pioneering research from the University of Pennsylvania, the company targets the molecular and epigenetic drivers of cardiac dysfunction and remodeling. Cormentum's approach leverages insights into the transcriptional regulation of heart muscle cells to identify novel therapeutic targets that can modify the course of the disease. Backed by prominent life science investors such as F-Prime Capital and GV (Google Ventures), the company is advancing a pipeline of first-in-class small molecule candidates. Cormentum is headquartered in Philadelphia, Pennsylvania, and aims to address the significant unmet medical need in chronic heart failure populations where current treatment options are limited.